{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:15Z","timestamp":1789726275273,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81374051"],"award-info":[{"award-number":["81374051"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074109"],"award-info":[{"award-number":["82074109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873078"],"award-info":[{"award-number":["81873078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374133"],"award-info":[{"award-number":["82374133"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.dmd.2025.100199","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:32:32Z","timestamp":1762360352000},"page":"100199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling"],"prefix":"10.1016","volume":"53","author":[{"given":"Yuan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adili","family":"Tuersun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmd.2025.100199_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/cph4.70003","article-title":"Type 2 diabetes mellitus: a comprehensive review of pathophysiology, comorbidities, and emerging therapies","volume":"15","author":"Singh","year":"2025","journal-title":"Compr Physiol"},{"key":"10.1016\/j.dmd.2025.100199_bib2","series-title":"IDF Diabetes Atlas","year":"2025"},{"key":"10.1016\/j.dmd.2025.100199_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"10365","key":"10.1016\/j.dmd.2025.100199_bib4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.dmd.2025.100199_bib5","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.dmd.2025.100199_bib6","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1345\/aph.1H060","article-title":"Exenatide: a new option for the treatment of type 2 diabetes","volume":"40","author":"Yoo","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.dmd.2025.100199_bib7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1159\/000510255","article-title":"Exenatide and renal outcomes in patients with type 2 diabetes and diabetic kidney disease","volume":"51","author":"Wang","year":"2020","journal-title":"Am J Nephrol"},{"issue":"11","key":"10.1016\/j.dmd.2025.100199_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3111\/13696998.2015.1067622","article-title":"Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with type 2 diabetes mellitus inadequately controlled by oral therapies","volume":"18","author":"Deng","year":"2015","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.dmd.2025.100199_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/17425255.2018.1420160","article-title":"Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes","volume":"14","author":"Molina Vega","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmd.2025.100199_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.dmd.2025.100199_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/138920006776873490","article-title":"Investigation of exenatide elimination and its in vivo and in vitro degradation","volume":"7","author":"Copley","year":"2006","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2125.2007.02890.x","article-title":"Effect of renal impairment on the pharmacokinetics of exenatide","volume":"64","author":"Linnebjerg","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100199_bib13","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1124\/dmd.111.042291","article-title":"Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans","volume":"40","author":"Gao","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"1\u20132","key":"10.1016\/j.dmd.2025.100199_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.016","article-title":"Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys","volume":"353","author":"Ai","year":"2008","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"10.1016\/j.dmd.2025.100199_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2008.01.015","article-title":"Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration","volume":"356","author":"Gedulin","year":"2008","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bcp.13135","article-title":"Population pharmacokinetics of exenatide","volume":"83","author":"Cirincione","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100199_bib17","doi-asserted-by":"crossref","first-page":"R490","DOI":"10.1152\/ajpregu.00495.2013","article-title":"Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor","volume":"306","author":"Tatarkiewicz","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100199_bib18","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1365-2125.2012.04416.x","article-title":"Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects","volume":"75","author":"Darp\u00f6","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100199_bib19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds","volume":"60","author":"An","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib20","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.diabres.2013.11.014","article-title":"Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists","volume":"103","author":"Dubois-Laforgue","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib21","first-page":"281","article-title":"Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus","volume":"19","author":"Bond","year":"2006","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/dc18-1760","article-title":"A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes","volume":"42","author":"Fayfman","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dmd.2025.100199_bib23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jphs.2014.12.004","article-title":"Target-mediated pharmacokinetic\/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus","volume":"127","author":"Li","year":"2015","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.dmd.2025.100199_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/17425255.1.1.159","article-title":"From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools","volume":"1","author":"Willmann","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmd.2025.100199_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114985","article-title":"Implications of ligand-receptor binding kinetics on GLP-1R signalling","volume":"199","author":"Zhao","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100199_bib26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10928-008-9102-8","article-title":"Approximations of the target-mediated drug disposition model and identifiability of model parameters","volume":"35","author":"Gibiansky","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"10.1016\/j.dmd.2025.100199_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clinthera.2005.02.008","article-title":"A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4)","volume":"27","author":"Calara","year":"2005","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.dmd.2025.100199_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"10.1016\/j.dmd.2025.100199_bib29","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1177\/0091270008323750","article-title":"Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus","volume":"48","author":"Kothare","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100199_bib30","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.clinthera.2009.04.005","article-title":"Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study","volume":"31","author":"Malloy","year":"2009","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.dmd.2025.100199_bib31","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40261-017-0569-1","article-title":"Pharmacokinetics and preliminary pharmacodynamics of single- and multiple-dose lyophilized recombinant glucagon-like peptide-1 receptor agonist (rE-4) in Chinese patients with type 2 diabetes mellitus","volume":"37","author":"Wang","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.dmd.2025.100199_bib32","series-title":"Physiologically Based Pharmacokinetic (PBPK) Modeling","first-page":"81","article-title":"Chapter 4\u2014physiologically based pharmacokinetic modeling software","author":"Hack","year":"2020"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/psp4.13099","article-title":"Population pharmacokinetics of the GIP\/GLP receptor agonist tirzepatide","volume":"13","author":"Schneck","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1s","key":"10.1016\/j.dmd.2025.100199_bib34","doi-asserted-by":"crossref","first-page":"130s","DOI":"10.18433\/jpps30028","article-title":"Understanding the monoclonal antibody disposition after subcutaneous administration using a minimal physiologically based pharmacokinetic model","volume":"21","author":"Varkhede","year":"2018","journal-title":"J Pharm Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.dmd.2025.100199_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/bdd.1994","article-title":"Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications","volume":"37","author":"Ferl","year":"2016","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2025.100199_bib37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/pharmaceutics17050604","article-title":"Accelerating biologics PBPK modelling with automated model building: a tutorial","volume":"17","author":"Derbalah","year":"2025","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.dmd.2025.100199_bib38","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/psp4.13262","article-title":"Local depletion of large molecule drugs due to target binding in tissue interstitial space","volume":"13","author":"Zasedateleva","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11095-012-0917-z","article-title":"Interspecies modeling and prediction of human exenatide pharmacokinetics","volume":"30","author":"Chen","year":"2013","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.dmd.2025.100199_bib40","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acs.molpharmaceut.2c00671","article-title":"Defining the intravital renal disposition of fluorescence-quenched exenatide","volume":"20","author":"Bryniarski","year":"2023","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.dmd.2025.100199_bib42","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/pharmaceutics15082129","article-title":"Translation of monoclonal antibodies pharmacokinetics from animal to human using physiologically based modeling in open systems pharmacology (OSP) suite: a retrospective analysis of bevacizumab","volume":"15","author":"Pasquiers","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.dmd.2025.100199_bib43","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/j.2040-4603.2012.tb00431.x","article-title":"Pathophysiology of acute kidney injury","volume":"2","author":"Basile","year":"2012","journal-title":"Compr Physiol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/08860221003611695","article-title":"Renal plasma flow and glomerular filtration rate duringacute kidney injury in man","volume":"32","author":"Prowle","year":"2010","journal-title":"Ren Fail"},{"issue":"5","key":"10.1016\/j.dmd.2025.100199_bib45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1016\/j.dmd.2025.100199_bib46","first-page":"S52","article-title":"A physiological approach to pharmacokinetics in chronic kidney disease","volume":"60","author":"Malik","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100199_bib47","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/toxics12060433","article-title":"Recent progress on physiologically based pharmacokinetic (PBPK) model: a review based on bibliometrics","volume":"12","author":"Huang","year":"2024","journal-title":"Toxics"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40265-013-0172-6","article-title":"Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.dmd.2025.100199_bib49","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1124\/dmd.110.037838","article-title":"A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions","volume":"39","author":"Strougo","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2025.100199_bib50","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1464-5491.2010.03009.x","article-title":"Exenatide and renal failure","volume":"27","author":"Ferrer-Garcia","year":"2010","journal-title":"Diabet Med"},{"issue":"2","key":"10.1016\/j.dmd.2025.100199_bib51","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.2337\/dc08-1309","article-title":"Exenatide-associated ischemic renal failure","volume":"32","author":"Weise","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.dmd.2025.100199_bib52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/acs.molpharmaceut.2c00737","article-title":"Mechanism-based pharmacokinetic modeling of absorption and disposition of a deferoxamine-based nanochelator in rats","volume":"20","author":"Jones","year":"2023","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.dmd.2025.100199_bib53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"10.1016\/j.dmd.2025.100199_bib54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10928-017-9547-8","article-title":"Fractional calculus in pharmacokinetics","volume":"45","author":"Sopasakis","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"10.1016\/j.dmd.2025.100199_bib55","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrendo.2014.202","article-title":"Gastric emptying and glycaemia in health and diabetes mellitus","volume":"11","author":"Phillips","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.dmd.2025.100199_bib56","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1111\/dom.13326","article-title":"Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: a quantitative assessment using an integrative systems pharmacology model","volume":"20","author":"Voronova","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.dmd.2025.100199_bib57","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jcph.1335","article-title":"General pharmacokinetic features of small-molecule compounds exhibiting target-mediated drug disposition (TMDD): a simulation-based study","volume":"59","author":"Bach","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100199_bib58","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/17425250902992901","article-title":"Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics","volume":"5","author":"Gibiansky","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100199_bib59","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/psp4.12553","article-title":"Novel mechanistic PBPK model to predict renal clearance in varying stages of CKD by incorporating tubular adaptation and dynamic passive reabsorption","volume":"9","author":"Huang","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100199_bib60","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s13300-020-00815-z","article-title":"Safety and efficacy of exenatide once weekly in participants with type 2 diabetes and stage 2\/3 chronic kidney disease","volume":"11","author":"Guja","year":"2020","journal-title":"Diabetes Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562509508X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562509508X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:58:55Z","timestamp":1777474735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562509508X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S009095562509508X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100199","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100199"}}